Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL50840 | 0.89 | MLLT1 (0.50) | GAAALDH1A1MAPTTSHRHSD17B10 | |
| SCHEMBL83409 | 0.89 | MLLT1 (0.52) | GAAALDH1A1MAPTTSHRHSD17B10 | |
| SCHEMBL3517823 | 0.88 | MEN1 (0.43) | POLBGAAALDH1A1MAPTTSHR | |
| SCHEMBL3518675 | 0.84 | MLLT1 (0.44) | POLBGAAALDH1A1MAPTTSHR | |
| SCHEMBL51858 | 0.79 | KDM4E (0.41) | SMN1; SMN2GAAALDH1A1MAPTTSHR | |
| SCHEMBL61188 | 0.79 | TNKS2 (0.50) | SMN1; SMN2GAAALDH1A1MAPTTSHR | |
| SCHEMBL3520029 | 0.78 | KDM4E (0.45) | SMN1; SMN2GAAALDH1A1MAPTTSHR | |
| SCHEMBL3515927 | 0.78 | KDM4E (0.40) | SMN1; SMN2GAAALDH1A1MAPTTSHR | |
| SCHEMBL50996 | 0.76 | KMT2A (0.41) | SMN1; SMN2GAAALDH1A1TSHRHSD17B10 | |
| SCHEMBL14550565 | 0.75 | GAA (0.45) | POLBGAAALDH1A1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141429-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EISAI INC. (US) | 2015-05-21 | — | — | US | disclosed |
| EP-2842956-A1 | PARP inhibitor compounds, compositions and methods of use | Eisai Inc. (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8894989-B2 | PARP inhibitor compounds, compositions and methods of use | EISAI INC. (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2209375-B1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EISAI INC (US) | 2014-08-27 | — | — | EP | disclosed |
| US-20130011365-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EISAI INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8236802-B2 | PARP inhibitor compounds, compositions and methods of use | EISAI INC. (US) | 2012-08-07 | — | — | US | disclosed |
| EP-2209375-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Eisai Inc. (US) | 2010-07-28 | — | — | EP | disclosed |
| US-20090098084-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MGI GP, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009046205-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EISAI RESEARCH INSTITUTE (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141429-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PARP1, PARP3, PARP2 | SMN1; SMN2 1340/4885POLB 45/4885THRB 3038/4885 |
| US-20090098084-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PARP1, PARP3, PARP2 | SMN1; SMN2 1340/4885POLB 45/4885THRB 3038/4885 |
| US-20130011365-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PARP1, PARP3, PARP2 | SMN1; SMN2 1615/4885POLB 50/4885THRB 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.